深度突变扫描鉴定MPL依赖性致癌转化的新驱动与修饰突变
研究采用深度突变扫描评估人血小板生成素受体跨膜域所有单氨基酸替换在Ba/F3细胞中赋予细胞因子非依赖性生长的能力,鉴定出所有已知驱动突变及7个新型组成性激活突变,并发现大量增强S505N驱动的第二位点突变;在MPN患者测序数据中验证了这些突变类别。
要点
- 深度突变扫描可系统鉴定MPL跨膜域驱动突变与增强突变。
- 发现7个新型组成性激活TpoR突变及多个增强S505N的突变。
- 患者数据支持新突变可能是MPN的驱动或修饰因素。
核心结论
- 深度突变扫描鉴定了所有已知MPL跨膜域驱动突变、7个新型组成性激活突变及大量增强S505N驱动的第二位点突变,患者数据提示这些新突变可能是MPN的驱动或修饰因素。
研究设计与样本
- 采用深度突变扫描方法评估人TpoR跨膜域所有可能的单氨基酸替换在Ba/F3细胞中赋予细胞因子非依赖性生长的能力。
主要发现
- 鉴定出所有目前已知的驱动突变和7个导致TpoR组成性激活的新型突变。
- 发现大量增强S505N驱动激活的第二位点突变。
- 在已发表和未发表的MPN患者MPL外显子10测序数据中发现了上述两类突变的实例。
关键数值与推荐
- 约6%的JAK2 V617F阴性原发性血小板增多症患者和约14%的JAK2 V617F阴性原发性骨髓纤维化患者具有经典MPL外显子10驱动突变W515L/K/R/A或S505N。
临床怎么用
- 对MPN患者MPL外显子10非经典突变进行功能解读时,可参考深度突变扫描鉴定的组成性激活或增强突变类别。
局限性
- 研究在Ba/F3细胞中进行,非经典突变在患者中的功能后果和疾病相关性在几乎所有病例中仍未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The single transmembrane domain (TMD) of the human thrombopoietin receptor (TpoR/myeloproliferative leukemia [MPL] protein), encoded by exon 10 of the MPL gene, is a hotspot for somatic mutations associated with myeloproliferative neoplasms (MPNs). Approximately 6% and 14% of JAK2 V617F- essential thrombocythemia and primary myelofibrosis patients, respectively, have "canonical" MPL exon 10 driver mutations W515L/K/R/A or S505N, which generate constitutively active receptors and consequent loss of Tpo dependence. Other "noncanonical" MPL exon 10 mutations have also been identified in patients, both alone and in combination with canonical mutations, but, in almost all cases, their functional consequences and relevance to disease are unknown. Here, we used a deep mutational scanning approach to evaluate all possible single amino acid substitutions in the human TpoR TMD for their ability to confer cytokine-independent growth in Ba/F3 cells. We identified all currently recognized driver mutations and 7 novel mutations that cause constitutive TpoR activation, and a much larger number of second-site mutations that enhance S505N-driven activation. We found examples of both of these categories in published and previously unpublished MPL exon 10 sequencing data from MPN patients, demonstrating that some, if not all, of the new mutations reported here represent likely drivers or modifiers of myeloproliferative disease.
引用
- Bridgford JL, Lee SM, Lee CMM, et al. Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood. 2020. PMID: 31697803. doi:10.1182/blood.2019002561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。